Aeterna Zentaris Inc. (AEZS) On December 28th Aeterna Zentaris announced that it has reached an agreement with the U.S. Food and Drug Administration (“FDA”) on a Special Protocol Assessment (“SPA”) for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. Optimistic market reaction on this announcement boosted AEZS shares […]